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Introduction
In the past, women with systemic lupus erythematosus
(SLE) were advised not to get pregnant due to fear of
disease flare-up. Many patients stopped their medica-
tions when they found themselves pregnant. Ironically,
this contributes to increased risk of disease flare-up,
especially in patients with active disease. The present
experience shows that the risk of pregnancy in SLE
patients is not unacceptably high for the mother or 
her baby, provided careful planning of conception and
multidisciplinary monitoring and treatment are carried
out. Specific factors associated with unfavorable fetal
outcome include active disease during pregnancy, renal
involvement, hypocomplementemia, antiphospholipid
antibodies, maternal hypertension, antibodies to Ro/
SS-A, and lymphotoxic antibodies. This article summa-
rizes the maternal and fetal outcome of 24 pregnan-
cies in 17 SLE patients in our hospital.
Materials and Methods
We retrospectively reviewed pregnancy outcome of
women with SLE in our hospital for the period between
January 2000 and February 2005. SLE patients with
active pregnancy were recruited. SLE was diagnosed
prior to contraception, according to the 1982 revised
criteria of the American Rheumatism Association. All
the patients were evaluated routinely for disease-related
manifestations and comorbidities every 3 months.
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SUMMARY
Objective: To study the maternal and fetal outcomes in women with systemic lupus erythematosus (SLE).
Materials and Methods: Over a period of 10 years, 24 pregnancies in 17 females with SLE in a single center
were enrolled. Fetal and maternal outcomes were studied retrospectively.
Results: The mean patient age was 27.7 years. Twenty-one of the 24 pregnancies occurred in the period of disease
remission at the time of conception. Proteinuria presented in 12 pregnancies; however, no patient developed acute
renal failure or deterioration of renal function. There were three cases of preeclampsia in this study. Two patients
had their disease flare up and delivered stillborns. One woman with secondary antiphospholipid syndrome (APS)
had a fetal loss. There was no maternal mortality. The mean gestation age was 34.3 weeks (range, 17–41 weeks),
and the mean birth weight was 2,179 g. The mean APGAR scores were 8 and 9 at 1 and 5 minutes, respectively. One
baby with congenital atrioventricular block was born to a mother with positive anti-SSA antibody. There were five
cases (20.8%) of intrauterine growth retardation and 10 preterm deliveries (41.6%) in this study.
Conclusion: Pregnancy is relatively safe in women with SLE in remission but should be considered as a high-risk
pregnancy. APS is associated with poor pregnancy outcome. The patient needs to cooperate with obstetricians
and physicians for optimal disease control and detailed monitoring throughout the gestation. [Taiwanese 
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During each visit, the following laboratory tests were
performed: complete blood count, serum creatinine,
protein, albumin, glucose, and uric acid, urinalysis and
24-hour urine protein excretion as well as immuno-
logic markers including complement (C3, C4), and anti-
dsDNA antibody. At the first visit during pregnancy,
antibodies to Sm, Ro/SS-A, La/SS-B, anticardiolipin,
all by enzyme-linked immunosorbent assay (ELISA),
and lupus anticoagulant by activated partial thrombo-
plastin time were assayed. Proteinuria was defined as
24-hour protein excretion  500 mg, and anemia as
hemoglobin  9 mg/dL. Premature birth (preterm) is
defined as live birth before 37 weeks of gestation, and
intrauterine growth retardation (IUGR) as birth weight
< 5th percentile of the normal growth curve; preeclamp-
sia, the evidence of proteinuria (> 300 mg/24 hours) and
hypertension, with or without edema, in patients with
normal blood pressure and no evidence of proteinuria
prior to 20 weeks of gestation, or a significant increase
in blood pressure and proteinuria or new abnormalities
in platelet count or liver enzyme levels in the presence of
preexisting hypertension and proteinuria. The criteria
for the identification of SLE flares are according to the
detection of new onset of anemia, lymphopenia, rise in
anti-ds DNA titers or evidence of increased proteinuria.
Results
The Table shows the characteristics of 24 pregnancies.
Nineteen patients with 26 pregnancies were identified.
Two pregnancies were terminated therapeutically. Only
24 pregnancies in 17 patients were studied. The mean
age of the patients was 28.3 ± 4.1 years (range, 23–37
years), and mean age at the time of SLE diagnosis was
23.4 ± 4.2. The mean disease duration prior to the cur-
rent pregnancy was 4.9 ± 2.9 years. Seven of the preg-
nancies (41.1%) were the first pregnancy for the patient,
eight (47%) were the second, and five (29.4%) were
the third. Seven patients had a history of abortion.
Pregestational characteristics
Eighteen pregnancies occurred during the period of
disease remission and eight patients had good disease
control with prednisolone dosage < 10 mg daily or
equivalent.
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Table. Characteristics of patients and babies delivered
No. Pregnancy Age of Disease Gestation Delivery Baby’s sex and
diagnosis (yr) duration (yr) age (wk) birth weight (g)
1 1st 16 11 39+ C/S F, 2,846 g
2 1st 15 20 39+ C/S F, 3,324 g
2nd — 21 39+ C/S F, 3,512 g
3rd — 22 38+ C/S F, 3,416 g
3 1st 24 8 17+ VED Dead fetus, 42 g
4 1st 27 3 34+ C/S F, 1,848 g
5 1st 24 5 38+ NSD F, 3,384 g
2nd — 7 38+ NSD M, 3,766 g
6 1st 22 1 35+ NSD F, 1,808 g
2nd — 2 34+ NSD F, 2,456 g
7 1st 21 8 31+ NSD M, 1,966 g
8 1st 19 10 37+ NSD M, 2,546 g
9 1st 18 6 41+ C/S F, 2,896 g
10 1st 26 0.5 38+ NSD F, 2,344 g
11 1st 29 1 39+ VED F, 2,846 g
12 1st 18 7 32+ NSD F, 1,464 g
13 1st 21 4 36+ NSD F, 1,900 g
14 1st 21 2 34+ C/S M, 2,638 g
2nd — 6 33+ C/S M, 2,198 g
15 1st 21 4 40+ C/S M, 2,520 g
2nd — 5 38+ C/S M, 3,000 g
16 1st 28 0.5 38+ NSD M, 2,340 g
2nd — 4 29+ CS Asphyxic, 1,174 g
17 1st 23 0.5 37+ NSD F, 2,242 g
NSD normal spontaneous delivery; C/S  cesarean section; VED vacuum extraction delivery; N 24 pregnancies.
Effects of SLE on pregnancy
The duration of pregnancy was 35.6 ± 4.9 weeks, (range,
17–41 weeks). Two (8.3%) pregnancies were termi-
nated due to loss of fetal heart beat. Of the 22 live birth
pregnancies (91.6%), preterm delivery occurred in eight
cases (33.3%). Four (18.1%) were associated with pre-
mature rupture of membranes, three (13.6%) with IUGR,
and two (9%) with preeclampsia. The cesarean section
rate was 45.8% and vaginal delivery rate was 54.2%.
There were 12 (50%) pregnancies in patients with lupus
nephropathy. Six of them ended before 37 weeks.
Anemia (hemoglobin < 11 g/dL) occurred in seven pa-
tients, thalassemia and other hemoglobinopathies
were excluded. Antiphospholipid syndrome was diag-
nosed in one female, with one stillborn. Preeclampsia
occurred in three women.
Effects of SLE on neonatal outcome
The mean neonatal birth weight was 2,436.3 ± 837 g
(range, 42–3,766), and mean Apgar score was 8.7 ± 0.6.
There were five cases of IUGR and no case of neonatal
lupus. Only one baby had congenital complete atrioven-
tricular block.
Effects of pregnancy on SLE
In total, five patients (19.2%) had experienced postges-
tational flare, four with increased proteinuria, and one
with leukopenia. Increased serum level of anti-double
stranded antibody was observed in a patient with dete-
riorated proteinuria. All five patients required adminis-
tration of prednisolone to maintain disease activity in
remission. However, the postgestational serum levels 
of C3 and C4 were not significantly lower than before
pregnancy. In other patients, there is no symptom indi-
cating disease flare-up, such as discoid rash, malar rash,
alopecia, photosensitivity, oral ulcers, and arthritis.
Discussion
Pregnancy in lupus was considered highly risky because
of high flare-up rate especially during late pregnancy or
postpartum [1]. Flare-up of disease occurs in 60% of
pregnant lupus patients, but in our study, we found a
lower rate of 19.2%. Renal and hematologic systems
are more commonly involved than the musculoskeletal
system. The rate in pregnancy (1.63 flares per person-
year) is more than the rate flared-up after pregnancy
(0.64), and more than in nonpregnant lupus patients
(0.65) [2]. Some studies found different pregnancy
outcomes in SLE patients. Lockshin [3] found a flare
rate of less than 13% if only SLE-specific abnormalities
were considered. In a retrospective analysis, no flare-up
of SLE caused by pregnancy was found. The disease
remained stable in about 30% of patients. Lupus activ-
ity was mild in the majority of women who carried out
their pregnancy to term. Mothers with active SLE can
successfully deliver the baby [4].
Pregnancy for patients with lupus is suggested only if
the disease has been inactive for 6 months and daily
prednisone dose is < 10 mg. However, the risk of fetal
loss and spontaneous abortion are still higher compared
to control population, despite the fact that the disease
is inactive at the onset of pregnancy [5]. Gordon men-
tioned that there are unreliable and reliable features for
diagnosing lupus flare-ups in pregnancy. Therefore, clini-
cians need to differentiate between normal physiologic
changes in pregnancy and pregnancy-related compli-
cations that may mimic lupus symptoms and signs [6].
Le Huong et al reported a high prematurity rate associ-
ated with lupus pregnancy, though without maternal or
neonatal death, and no correlation between prematurity
and SLE activity [7]. Proteinuria, hypertension, and pos-
itive antiphospholipid antibodies are independent pre-
dictors of adverse fetal outcome in pregnancy with
lupus nephritis [8]. Presence of anti-Ro/SSA is only
responsible for fetal congenital heart block, but has no
significant effect on pregnancy outcome [9]. Differentia-
ting active lupus nephritis from preeclampsia is critical,
although they could co-exist. The presence of hyper-
tension in a patient with recent onset of proteinuria
make preeclampsia more likely than lupus nephritis [10].
Measurement of flare in pregnancy could be difficult,
but some criterion has been developed recently for mea-
suring it. Lupus activity index in pregnancy is strongly
recommended for detecting flare-up of lupus during
pregnancy and puerperium for its high sensitivity, speci-
ficity and predictive values and likelihood ratios [11].
NSAID or COX-2 inhibitors are not teratogenic, but
due to their side effects to the fetus, especially during late
pregnancy, these drugs should be discontinued after
32 gestational weeks [12] or 8 weeks prior to expected
delivery [13]. The use of hydroxychloroquine (HCQ) is
controversial [14]. Some recommend discontinuation
because it can cross the placenta, and its concentration
in cord blood is identical to that found in maternal
blood [15]. However, in a double-blind and placebo-
controlled study, the HCQ group could taper predniso-
lone to a lower dose compared to the placebo group.
The delivery age and Apgar score are higher without con-
genital abnormalities [16]. These research support pre-
liminary evidence for the safety of HCQ therapy during
pregnancy and it is suggested that therapy be main-
tained throughout pregnancy in SLE patients [17].
Low-dose corticosteroid is relatively safe to the fetus
but increased risk of premature birth due to rupture of
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membranes and low birth weight may occur [18].
Increased risk of isolated cleft lip with or without cleft
palate, and isolated cleft palate have been reported [19].
The neonatal effect in a mother taking prednisolone
20 mg/day or less is insignificant. Prednisolone and
methylprednisolone have little placental transfer, but
fluorinated corticosteroids like dexamethasone and
betamethasone easily cross the placenta and should be
avoided during pregnancy. Prophylaxis for postpartum
flare with corticosteroid is not necessary [20]. Cyclos-
porine and azathioprine can be given throughout preg-
nancy if required for active disease control [21].
In our observation, patient with disease remission
can be safely pregnant, and has a lower flare rate (7.7%).
The most frequent complication is preterm labor and
the most severe complication seemed to be associated
with antiphospolipid syndrome. Low-dose prednisolone
is necessary to maintain remission throughout preg-
nancy. Pregnancy in women with lupus should be man-
aged as high-risk pregnancies with optimal care provided
by obstetricians and physicians.
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